schliessen

Filtern

 

Bibliotheken

Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study

Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to norm... Full description

Journal Title: Diabetes care September 2011, Vol.34(9), pp.1902-7
Main Author: Barzilay, Joshua I
Other Authors: Gao, Peggy , Rydén, Lars , Schumacher, Helmut , Probstfield, Jeffrey , Commerford, Patrick , Dans, Antonio , Ferreira, Rafael , Keltai, Mátyás , Paolasso, Ernesto , Yusuf, Salim , Teo, Koon
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1935-5548 ; PMID: 21788624 Version:1 ; DOI: 10.2337/dc11-0545
Link: http://pubmed.gov/21788624
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline21788624
title: Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study
format: Article
creator:
  • Barzilay, Joshua I
  • Gao, Peggy
  • Rydén, Lars
  • Schumacher, Helmut
  • Probstfield, Jeffrey
  • Commerford, Patrick
  • Dans, Antonio
  • Ferreira, Rafael
  • Keltai, Mátyás
  • Paolasso, Ernesto
  • Yusuf, Salim
  • Teo, Koon
subjects:
  • Benzimidazoles -- Therapeutic Use
  • Benzoates -- Therapeutic Use
  • Blood Glucose -- Drug Effects
  • Cardiovascular Diseases -- Blood
  • Diabetes Mellitus -- Blood
ispartof: Diabetes care, September 2011, Vol.34(9), pp.1902-7
description: Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.
language: eng
source:
identifier: E-ISSN: 1935-5548 ; PMID: 21788624 Version:1 ; DOI: 10.2337/dc11-0545
fulltext: fulltext
issn:
  • 19355548
  • 1935-5548
url: Link


@attributes
ID1530445731
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid21788624
sourceidmedline
recordidTN_medline21788624
sourceformatXML
sourcesystemPC
pqid896393050
galeid273528213
display
typearticle
titleEffects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study
creatorBarzilay, Joshua I ; Gao, Peggy ; Rydén, Lars ; Schumacher, Helmut ; Probstfield, Jeffrey ; Commerford, Patrick ; Dans, Antonio ; Ferreira, Rafael ; Keltai, Mátyás ; Paolasso, Ernesto ; Yusuf, Salim ; Teo, Koon
ispartofDiabetes care, September 2011, Vol.34(9), pp.1902-7
identifier
subjectBenzimidazoles -- Therapeutic Use ; Benzoates -- Therapeutic Use ; Blood Glucose -- Drug Effects ; Cardiovascular Diseases -- Blood ; Diabetes Mellitus -- Blood
descriptionSeveral large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia. Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care. During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo. There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.
languageeng
source
version10
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/21788624$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Barzilay, Joshua I
1Gao, Peggy
2Rydén, Lars
3Schumacher, Helmut
4Probstfield, Jeffrey
5Commerford, Patrick
6Dans, Antonio
7Ferreira, Rafael
8Keltai, Mátyás
9Paolasso, Ernesto
10Yusuf, Salim
11Teo, Koon
titleEffects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study
description
0Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia.
1Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care.
2During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo.
3There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.
subject
0Benzimidazoles -- Therapeutic Use
1Benzoates -- Therapeutic Use
2Blood Glucose -- Drug Effects
3Cardiovascular Diseases -- Blood
4Diabetes Mellitus -- Blood
general
021788624
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.2337/dc11-0545
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline21788624
issn
019355548
11935-5548
rsrctypearticle
creationdate2011
addtitleDiabetes care
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41201109
citationpf 1902 vol 34 issue 9
startdate20110901
enddate20110931
lsr30VSR-Enriched:[galeid, issn, pqid, pages]
sort
titleEffects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study
authorBarzilay, Joshua I ; Gao, Peggy ; Rydén, Lars ; Schumacher, Helmut ; Probstfield, Jeffrey ; Commerford, Patrick ; Dans, Antonio ; Ferreira, Rafael ; Keltai, Mátyás ; Paolasso, Ernesto ; Yusuf, Salim ; Teo, Koon
creationdate20110900
lso0120110900
facets
frbrgroupid2622660060742908743
frbrtype5
newrecords20190701
languageeng
creationdate2011
topic
0Benzimidazoles–Therapeutic Use
1Benzoates–Therapeutic Use
2Blood Glucose–Drug Effects
3Cardiovascular Diseases–Blood
4Diabetes Mellitus–Blood
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Barzilay, Joshua I
1Gao, Peggy
2Rydén, Lars
3Schumacher, Helmut
4Probstfield, Jeffrey
5Commerford, Patrick
6Dans, Antonio
7Ferreira, Rafael
8Keltai, Mátyás
9Paolasso, Ernesto
10Yusuf, Salim
11Teo, Koon
jtitleDiabetes Care
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Barzilay
1Gao
2Rydén
3Schumacher
4Probstfield
5Commerford
6Dans
7Ferreira
8Keltai
9Paolasso
10Yusuf
11Teo
aufirst
0Joshua I
1Peggy
2Lars
3Helmut
4Jeffrey
5Patrick
6Antonio
7Rafael
8Mátyás
9Ernesto
10Salim
11Koon
au
0Barzilay, Joshua I
1Gao, Peggy
2Rydén, Lars
3Schumacher, Helmut
4Probstfield, Jeffrey
5Commerford, Patrick
6Dans, Antonio
7Ferreira, Rafael
8Keltai, Mátyás
9Paolasso, Ernesto
10Yusuf, Salim
11Teo, Koon
atitleEffects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study
jtitleDiabetes care
risdate201109
volume34
issue9
spage1902
pages1902-1907
eissn1935-5548
formatjournal
genrearticle
ristypeJOUR
abstractSeveral large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia.
doi10.2337/dc11-0545
pmid21788624
issn01495992
date2011-09